Therapeutic Drug Monitoring of Vedolizumab Levels During Maintenance in Inflammatory Bowel Disease ( <scp>MOVE</scp> ‐ <scp>IBD</scp> )
Vedolizumab trough levels were not associated with clinical or objective remission during maintenance therapy, and in our real-world cohort, do not appear to be a clinically relevant target for TDM.
Authors
- K Rimmer
- James D. Doecke (ORCID: https://orcid.org/0000-0003-2863-0293)
- Hayley Logan
- Desmond Patrick (ORCID: https://orcid.org/0000-0002-1367-6945)
Institutions
- Griffith University (AU)
- Royal Brisbane and Women's Hospital (AU)
- Sunshine Coast University Hospital (AU)
- Australian e-Health Research Centre (AU)
- CSIRO Health and Biosecurity (AU)
Publication Details
- Journal
- JGH Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/jgh3.70320
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00